Usama Malik, CEO, Fore Biotherapeutics is aiming to treat patients with rare cancer mutations with a hyper targeted precision or personalized approach by using the Fore AI-based technology platform to investigate which drugs might work best for each mutation. While most cancer companies focus only on the most prevalent mutations, Fore is expanding the search by looking at hundreds of mutations to identify driver mutations that actively contribute to the growth of tumors. Fore is in search of unaddressed patient populations and patients where existing therapeutics are not working. #ForeBiotherapeutics #cancer #raredisease #oncology #BRAF #precisionmedicine #personalizedmedicine #DriverMutations Fore.Bio Download the transcript here